Dexmedetomidine as an Adjunct to Anti-Hypertensive Medication in Hemodynamic Management of Post-Operative Young Patients with Pre-Eclampsia
DOI:
https://doi.org/10.51253/pafmj.v75i2.12575Keywords:
Adjunct anti-hypertensive, Dexmedetomidine, Pre-eclampsiaAbstract
Objective: To compare hemodynamic stability and patient outcomes when using dexmedetomidine as an adjunct to anti-hypertensive medication in post-operative young patients with pre-eclampsia
Study Design: Quasi-experimental study
Place and Duration of Study: Department of Anesthesia, Combined Military Hospital Bannu, Pakistan from 15 Jan - 15 Dec 2023.
Methodology: A total of 180 patients were recruited for this quasi-experimental study. Patients were divided into Group-D (n=80) to receive Dexmedetomidine along with standard anti-hypertensive therapy, which included intravenous Labetalol, and Group-S (n=80) to receive standard anti-hypertensive therapy with intravenous Labetalol alone. Primary variables studied were hemodynamic profile in all patients, including heart rate and blood pressure checked at 1,3,6,12,18, and 24 hours. Secondary variables studied were sedation levels, mean total dose of analgesia required for post-operative pain in 24 hours, and the incidence of adverse effects including bradycardia, hypotension, nausea/vomiting and headache.
Results: Mean arterial pressure (MAP) after 01 hour of therapy between Group-D and Group-S was 98.64±1.63 mmHg versus 100.55±4.75 mmHg (p=0.001), after 03 hours of therapy was 85.56±1.27 mmHg versus 89.13±2.29 mmHg (p<0.001), after 06 hours of therapy was 77.56±1.36 versus 89.35±2.90 mmHg (p<0.001), after 12 hours of therapy was 74.33±1.38 mmHg versus 82.94±4.26 mmHg (p<0.001), after 18 hours of therapy was 70.46±0.82 mmHg versus 78.61±0.60 mmHg (p<0.001) and after 24 hours of therapy was 67.99±1.08 mmHg versus 78.64±0.57 mmHg (p <0.001).
Conclusion: Addition of Dexmedetomidine to standard anti-hypertensive therapy results in a better hemodynamic profile, better patient comfort, less requirement for analgesia with a tolerable adverse effects profile.
Downloads
References
et al. The impact of the definition of preeclampsia on disease diagnosis and outcomes: a retrospective cohort study. Am J Obstet Gynecol 2021; 224(2): 217. e1-. e11. https://doi.org/10.1016/j.ajog.2020.08.019
Lai J, Syngelaki A, Nicolaides KH, von Dadelszen P, Magee LA. Impact of new definitions of preeclampsia at term on identification of adverse maternal and perinatal outcomes. Am J Obstet Gynecol 2021; 224(5): 518. e1-. e11. https://doi.org/10.1016/j.ajog.2020.11.004
Sole KB, Staff AC, Räisänen S, Laine K. Substantial decrease in preeclampsia prevalence and risk over two decades: a population-based study of 1,153,227 deliveries in Norway. Pregnancy Hypertens 2022; 28: 21-27. https://doi.org/10.1016/j.preghy.2022.02.001
Ahmad A, Mohammed SB, Sohail M, Ashraf HS, Safdar Z, Asghar M. Prevalence of Preeclampsia in Adolescent. J Therapies Rehabil Sci 2020: 03-8. https://doi.org/10.54393/tt.v1i2.16
Magee LA, Wright D, Syngelaki A, von Dadelszen P, Akolekar R, Wright A, et al. Preeclampsia prevention by timed birth at term. Hypertension 2023; 80(5): 969-978. https://doi.org/10.1161/HYPERTENSIONAHA.122.20565
Magee L, Singer J, Lee T, Rey E, Asztalos E, Hutton E, et al. The impact of pre‐eclampsia definitions on the identification of adverse outcome risk in hypertensive pregnancy–analyses from the CHIPS trial (Control of Hypertension in Pregnancy Study). BJOG: Int J Obstet Gynaecol 2021; 128(8): 1373-1382. https://doi.org/10.1111/1471-0528.16602
Nirupama R, Divyashree S, Janhavi P, Muthukumar S, Ravindra P. Preeclampsia: Pathophysiology and management. J Gynecol Obstet Hum Reprod 2021; 50(2): 101975. https://doi.org/10.1016/j.jogoh.2020.101975
Liaquat Z, Xu X, Zilundu PLM, Fu R, Zhou L. The current role of dexmedetomidine as neuroprotective agent: an updated review. Brain Sci. 2021; 11(7): 846. https://doi.org/10.3390/brainsci11070846
El-Arab NKE, El-Hawary SI, El-Zeftawy AE, Mohammed RM. Dexmedetomidine in preeclamptic patients undergoing caesarean section under general anesthesia. Tanta Med J 2017; 45(4): 220-225. http://doi.org/ 10.4103/tmj.tmj_35_17
Motlagh SD, Rokhtabnak F, Ghodraty MR, Delarestaghi MM, Saadat S, Araghi Z. Effect of different loading doses of dexmedetomidine on controlled hypotension and the incidence of bradycardia during rhinoplasty: a clinical trial. Anesthesiol Pain Med 2021; 11(4). https://doi.org/10.5812%2Faapm.118857
De Queiroz DV, Velarde LGC, Alves RL, Verçosa N, Cavalcanti IL. Incidence of bradycardia during noradrenaline or phenylephrine bolus treatment of postspinal hypotension in cesarean delivery: A randomized double‐blinded controlled trial. Acta Anaesthesiol Scand 2023; 67(6): 797-803. https://doi.org/10.1111/aas.14225
Nugent SM, Lovejoy TI, Shull S, Dobscha SK, Morasco BJ. Associations of pain numeric rating scale scores collected during usual care with research administered patient reported pain outcomes. Pain Med 2021; 22(10): 2235-2241. https://doi.org/10.1093/pm/pnab110
Lewis K, Alshamsi F, Carayannopoulos KL, Granholm A, Piticaru J, Al Duhailib Z, et al. Dexmedetomidine vs other sedatives in critically ill mechanically ventilated adults: a systematic review and meta-analysis of randomized trials. Intensive Care Med 2022; 48(7): 811-840. https://doi.org/10.1007/s00134-022-06712-2
Liu X, Li Y, Kang L, Wang Q. Recent advances in the clinical value and potential of dexmedetomidine. J Inflamm Res 2021: 7507-7527. https://doi.org/10.2147/jir.s346089
Afandy ME, Abusabaa M, Lotfy HA, Mansour RF. Effect of the use of dexmedetomidine as a local anesthetic adjuvant to bupivacaine 0.125% in epidural labor analgesia: randomized controlled study. Ain-Shams J Anesthesiol 2021; 13(1). https://doi.org/10.1186/s42077-021-00196-w
Salah J, Grgurich P, Nault K, Lei Y. Identification of risk factors for hypertension and tachycardia upon dexmedetomidine discontinuation. J Crit Care 2020; 59: 81-85. https://doi.org/10.1016/j.jcrc.2020.06.006
Bromfalk Å, Myrberg T, Walldén J, Engström Å, Hultin M. Preoperative anxiety in preschool children: A randomized clinical trial comparing midazolam, clonidine, and dexmedetomidine. Pediatr Anesth 2021; 31(11): 1225-33. https://doi.org/10.1111/pan.14279
Bao N, Tang B. Organ-protective effects and the underlying mechanism of dexmedetomidine. Mediators Inflamm 2020; 2020: 6136105.
Downloads
Published
License
Copyright (c) 2025 Muhammad Faisal Nadeem, Ihtisham Ul Haq, Muhammad Asghar, Farhat Afshan Jelani
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
